BRIEF-Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection

Reuters
10 Jun
BRIEF-Sino Biopharmaceutical Updates On Phase III Registrational Clinical Study Of TQB2868 Injection

June 10 (Reuters) - Sino Biopharmaceutical Ltd 1177.HK:

  • CDE APPROVAL TO INITIATE PHASE III REGISTRATIONAL CLINICAL STUDY OF TQB2868 INJECTION PD-1/TGF- BI-FUNCTIONAL FUSION PROTEIN

Further company coverage: 1177.HK

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10